Skip to the page

Data / Drug companies / Quagen Pharmaceuticals LLC

Quagen Pharmaceuticals LLC: 53 products in the FDA NDC directory, labeler code 70752

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Quagen Pharmaceuticals LLC (labeler code 70752) lists 53 products in the FDA National Drug Code Directory, covering 27 finished drugs by generic name. By type: 51 prescription drugs, 2 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 15, 2026.

The request: Watch Quagen Pharmaceuticals LLC (FDA labeler code 70752): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
70752
Products in commercial distribution
53
Packages
96
Finished drugs by generic name
27
Prescription products
51
Over the counter products
2
Controlled substance products
Schedule II 4, Schedule III 5, Schedule IV 8, Schedule V 1
Flagged as original packager
50 of 50 products that carry the flag
Started marketing in the last 12 months
6
Earliest marketing start
May 22, 2019
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)4483%
Other unapproved drugs917%

Products by type

TypeProductsShare
Prescription drugs5196.2%
Over the counter drugs23.8%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet2037.7%
Solution1834%
Oil35.7%
Lotion23.8%
Ointment23.8%
Capsule23.8%
Tablet, extended release23.8%
Powder, for suspension11.9%
Suppository11.9%
Paste11.9%
Syrup11.9%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Cyproheptadine hydrochloride70752-232TabletGeneric drugs (ANDA)October 15, 2026
Niacin70752-296Tablet, extended releaseGeneric drugs (ANDA)August 6, 2026
Niacin70752-295Tablet, extended releaseGeneric drugs (ANDA)August 6, 2026
Mycophenolate Mofetil70752-294Powder, for suspensionGeneric drugs (ANDA)August 6, 2026
Glycopyrrolate70752-175SolutionGeneric drugs (ANDA)August 1, 2026
Aripiprazole70752-114SolutionGeneric drugs (ANDA)December 15, 2025
Benztropine mesylate70752-125TabletGeneric drugs (ANDA)August 11, 2025
Benztropine mesylate70752-124TabletGeneric drugs (ANDA)August 11, 2025
Benztropine mesylate70752-123TabletGeneric drugs (ANDA)August 11, 2025
Fluocinonide70752-154SolutionGeneric drugs (ANDA)March 15, 2025
Levetiracetam70752-203SolutionGeneric drugs (ANDA)February 1, 2025
Glycopyrrolate70752-109TabletGeneric drugs (ANDA)October 10, 2024
Glycopyrrolate70752-108TabletGeneric drugs (ANDA)October 10, 2024
BUTALBITAL and ACETAMINOPHEN70752-148TabletGeneric drugs (ANDA)May 1, 2024
BUTALBITAL and ACETAMINOPHEN70752-147TabletGeneric drugs (ANDA)May 1, 2024
Butalbital, acetaminophen and caffeine70752-144CapsuleGeneric drugs (ANDA)May 1, 2024
Butalbital, acetaminophen and caffeine70752-142TabletGeneric drugs (ANDA)May 1, 2024
Valproic acid70752-202SolutionGeneric drugs (ANDA)April 15, 2024
Cyproheptadine hydrochloride70752-185SolutionGeneric drugs (ANDA)December 22, 2023
Folic Acid70752-231TabletGeneric drugs (ANDA)July 10, 2023
Triamcinolone acetonide70752-140PasteGeneric drugs (ANDA)January 15, 2023
Cetirizine hydrochloride70752-104SolutionGeneric drugs (ANDA)October 15, 2022
Cetirizine hydrochloride70752-103SolutionGeneric drugs (ANDA)October 15, 2022
Butalbital, acetaminophen and caffeine70752-141CapsuleGeneric drugs (ANDA)August 6, 2022
Hydrocortisone Acetate70752-169SuppositoryOther unapproved drugsJuly 18, 2022

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.